Semaglutide (marketed under brand names such as Ozempic and Wegovy) is a GLP-1 receptor agonist prescribed for weight management, blood sugar control in type 2 diabetes, and the reduction of major cardiovascular risks including heart attack and stroke in certain patients.
Administered once weekly by subcutaneous injection, Semaglutide works by mimicking the action of the natural hormone GLP-1. It stimulates insulin release in response to meals, reduces the secretion of glucagon, slows the rate of gastric emptying, and helps curb appetite. Together, these mechanisms contribute to improved glucose regulation, sustained weight loss, and better overall metabolic health.
🔬 Research Applications (Non‑Medical)
Used in peptide‑signaling research involving GLP‑1 receptor pathways.
Supports studies on cAMP‑linked intracellular signaling, peptide–receptor affinity, and metabolic‑pathway modeling.
Applied in in‑vitro systems evaluating peptide stability, enzymatic degradation, and sequence‑dependent behavior.
Suitable for analytical method development for long‑chain peptides.
🧬 Molecular Characteristics
Type: Modified GLP‑1 analog with fatty‑acid conjugation.
Form: Lyophilized powder (10mg).
Identity: Verified via MS and HPLC/UPLC.
Biochemical Notes:
Stability: Sensitive to oxidation and hydrolysis in solution.
❄️ Storage & Handling
Store at –20°C, protected from light.
Reconstituted solutions should be stored at 2–8°C and used promptly.
📄 Documentation / COA Visibility
⚠️ Compliance Notice
Semiglutide is supplied for laboratory research only. Not for human or veterinary use. No therapeutic, metabolic, or performance‑related claims are made or implied.
Semaglutide (marketed under brand names such as Ozempic and Wegovy) is a GLP-1 receptor agonist prescribed for weight management, blood sugar control in type 2 diabetes, and the reduction of major cardiovascular risks including heart attack and stroke in certain patients.
Administered once weekly by subcutaneous injection, Semaglutide works by mimicking the action of the natural hormone GLP-1. It stimulates insulin release in response to meals, reduces the secretion of glucagon, slows the rate of gastric emptying, and helps curb appetite. Together, these mechanisms contribute to improved glucose regulation, sustained weight loss, and better overall metabolic health.
🔬 Research Applications (Non‑Medical)
Used in peptide‑signaling research involving GLP‑1 receptor pathways.
Supports studies on cAMP‑linked intracellular signaling, peptide–receptor affinity, and metabolic‑pathway modeling.
Applied in in‑vitro systems evaluating peptide stability, enzymatic degradation, and sequence‑dependent behavior.
Suitable for analytical method development for long‑chain peptides.
🧬 Molecular Characteristics
Type: Modified GLP‑1 analog with fatty‑acid conjugation.
Form: Lyophilized powder (10mg).
Identity: Verified via MS and HPLC/UPLC.
Biochemical Notes:
Stability: Sensitive to oxidation and hydrolysis in solution.
❄️ Storage & Handling
Store at –20°C, protected from light.
Reconstituted solutions should be stored at 2–8°C and used promptly.
📄 Documentation / COA Visibility
⚠️ Compliance Notice
Semiglutide is supplied for laboratory research only. Not for human or veterinary use. No therapeutic, metabolic, or performance‑related claims are made or implied.
